Page 94 - e-CPG-SLE-8_5_24

Management of Systemic Lupus Erythematosus

ELISA enzyme-linked immunosorbent assay
EMG electromyogram
ENA extractable nuclear antigens
ESR erythrocyte sedimentation rate
EULAR European Alliance of Associations for Rheumatology
EULAR/ACR European Alliance of Associations for Rheumatology/American
College of Rheumatology
EXPLORER Exploratory Phase II/III SLE Evaluation of Rituximab
FBC full blood count
FRAX fracture risk assessment tool
g gram
GI gastrointestinal
GRADE Grading Recommendations, Assessment, Development and Evaluation
h hour
HCQ hydroxychloroquine
hpf high power field
HPV human papillomavirus
HR hazard ratio
HRT hormone replacement therapy
HTA health technology assessment
HZ Herpes Zoster
ICU intensive care unit
IgA immunoglobulin A
IgG immunoglobulin G
IgM immunoglobulin M
IIF indirect immunofluorescence
IQR interquartile range
IUD intrauterine device
IV intravenous
IVIG intravenous immunoglobulin
kg kilogram
LA lupus anticoagulant
LDA low dose aspirin
LFT liver function test
LLDAS lupus low disease activity state
LN lupus nephritis
LUNAR Lupus Nephritis Assessment with Rituximab
m 2 square metre
MaHTAS Malaysian Health Technology Assessment Section
MD mean difference
mg milligram
min minute
mL millilitre
MMF mycophenolate mofetil
MRI magnetic resonance imaging
mRNA messenger RNA
MTX methotrexate
MOH Ministry of Health
NIH National Institutes of Health
NPSLE neuropsychiatric SLE
NSAID nonsteroidal anti-inflammatory drug
OD once a day

77